Generics & Biosimilars | Association for Accessible Medicines
AAM All Access Podcast - Dan Leonard speaks to AAM's Lisa Parks and Monét Stanford
Learn More
Close
  • AAM All Access Podcast
    AAM All Access Podcast: Pharmacists Month
    AAM CEO Dan Leonard is joined by Sciences & Regulatory Affairs VP Lisa Parks and Policy Director Monét Stanford—both registered pharmacists—to talk about the role of pharmacists in patient care and the future of pharmacy.
    Listen to Podcast
  • GRx+Biosims 2021 Welcome Gift
    GRx+Biosims 2021
    Register for GRx+Biosims 2021 today to receive your special welcome gift. Supplies are limited.
    Register Now
  • 2nd Annual Global Biosimilars Week
    Global Biosimilars Week 2021
    Save the Date! The second annual #GlobalBiosimilarsWeek to celebrate the advancement of biosimilars across the world will be held November 1-5!
    Learn More
  • AAM 2021 U.S. Generic and Biosimilar Medicines Savings Report. October 2021.
    2021 U.S. Generic and Biosimilar Medicines Savings Report
    Report reveals continued savings growth through lower-cost generic and biosimilar competition. The findings reinforce the outsized importance of the industry delivering lifesaving & health-managing medicines.
    View Full Report
  • Pharmacist holding an Rx bottle and talking to a patient
    U.S. Generic and Biosimilar Savings Totaled a Record $338 Billion in 2020
    AAM releases topline findings from its forthcoming 2021 U.S. Generic and Biosimilar Medicines Savings report highlighting the value of generic and biosimilar medicines.
    Read Press Release
  • Janet Woodcock, M.D. Acting Commissioner, FDA
    FDA Acting Commissioner to Speak at GRx+Biosims
    Dr. Janet Woodcock will bring invaluable insights on generics and biosimilars during this public health emergency. Sign up for GRx+Biosims 2021 now and enjoy $300 in savings.
    Register Now
  • GRx+Biosims 2021: Generics & Biosimilars Conference — Progress + Process
    GRx+Biosims 2021
    Hear the latest from top-in-their-field speakers and government officials, connect with peers from around the world and explore new learning tracks in the generics and biosimilars industry. November 8-10, 2021. Sign up for GRx+Biosims 2021 now and enjoy $300 in savings!
    Watch Video
  • AAM All Access Podcast
    AAM All Access Podcast: Dan Leonard and Jeff Watson
    Dan Leonard speaks with Apotex President and CEO Jeff Watson on the history and vision of the manufacturer and a future of “tremendous opportunity” for generics.
    Listen to Podcast
  • ""
    Industry Response to COVID-19
    The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.
    Learn More
  • AAM Report: New Generics Are Less Available in Medicare Than Commercial Plans
    New Generics Are Less Available in Medicare Than Commercial Plans
    AAM releases a new report confirming Medicare Part D plans continue to fail to get new generics to patients.
    Read Report
  • RxFacts
    What We Know—and What We Don’t
    In the past two decades, misunderstood and exaggerated stats regarding the generics supply chain have been cited.
    View #RxFacts
  • Take with Confidence
    Take With Confidence
    Generic Prescription Drugs: Your Health. Our Commitment.
    Learn More
  • AAM Patient Report: Voices of Access
    Patient Stories: Voices of Access
    AAM's Voices of Access report features patients across the country who tell the impact of accessible generic and biosimilar medicines.
    Meet the AAM Patients
  • Interactive Savings Map 2020
    Health Care Savings, State by State
    The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?
    Read Blog

Working to leave a positive impact on...

Industry Industry We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More
People People We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More
Policy Policy We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Who We Are

Recent Updates

Association for Accessible Medicines

601 New Jersey Ave NW, Suite 850
Washington DC 20001

 

202.249.7100
info@accessiblemeds.org

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.